Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SHR-1802
i
Other names:
SHR-1802, SHR1802, SHR 1802
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Jiangsu Hengrui Pharma
Drug class:
LAG-3 inhibitor
Related drugs:
‹
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
LBL-007 (0)
Sym022 (0)
TNRX-257 (0)
TQB2223 (0)
ZGGS15 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
LBL-007 (0)
Sym022 (0)
TNRX-257 (0)
TQB2223 (0)
ZGGS15 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. (PubMed, Ther Adv Med Oncol)
Further studies with larger sample size and in combination forms are warranted for future clinical application. NCT04414150.
over 1 year ago
P1 data • PK/PD data • Journal • Metastases
|
SHR-1802
over1year
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=132, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
over 1 year ago
Enrollment open • Combination therapy • Metastases
|
cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ariely (adebrelimab) • SHR-1802
over2years
A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P2, N=124, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802
almost3years
A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P2, N=124, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
almost 3 years ago
New P2 trial
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login